Global InformationMirvetuximab soravtansine information
 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric |
| Target | folate receptor alpha |
| Clinical data | |
| Trade names | Elahere |
| Other names | mirvetuximab soravtansine-gynx |
| License data |
|
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| UNII |
|
| KEGG |
|
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.[2][3] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.[3][4]
The most common adverse reactions, including laboratory abnormalities, were vision impairment, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased neutrophils, and decreased hemoglobin.[3]
Mirvetuximab soravtansine was approved for medical use in the United States in November 2022.[3][5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6][7]
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ a b "Elahere- mirvetuximab soravtansine injection, solution". DailyMed. 18 November 2022. Retrieved 4 December 2022.
- ^ a b c d "FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer". U.S. Food and Drug Administration (FDA). 14 November 2022. Retrieved 18 November 2022.
This article incorporates text from this source, which is in the public domain.
- ^ "FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer". U.S. Food and Drug Administration (FDA). 22 March 2024. Retrieved 23 March 2024. This article incorporates text from this source, which is in the public domain.
- ^ Heo YA (February 2023). "Mirvetuximab Soravtansine: First Approval". Drugs. 83 (3): 265–273. doi:10.1007/s40265-023-01834-3. PMID 36656533. S2CID 255972733.
- ^ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
- ^ New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.
